UK Rejects Rx-To-OTC Switch Of Overactive Bladder Treatment
Executive Summary
Maxwellia’s application to switch to non-prescription status in the UK Aquiette (oxybutynin hydrochloride) for the treatment of overactive bladder has been rejected by MHRA following a public consultation.